Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe active lupus, a retrospective study shows.

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...